WHC is still in active development. Read this to understand our approach.
depiction of KWTWDQCKEHXFFR-UHFFFAOYSA-N.svg
tripsit

tapentadol

Verificar en tripsit

psychonaut

Tapentadol

Verificar en psychonaut

isomerdesign

Tapentadol

Verificar en isomerdesign

pubchem

Tapentadol

Verificar en pubchem

druglab

Tapentadol

Verificar en druglab

wiki

Tapentadol

Verificar en wiki

Data

InChI: InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3

Sinónimos: DB06204,Palexia,CS-M0020,Phenol,3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-,3-[(2R,3R)-1-dimethylamino-2-methylpentan-3-yl]phenol,SCHEMBL116924,TAPENTADOL [VANDF],3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol,CG-5503,AR-270/43507984,R-331333,3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol,TAPENTADOL [MI],A26964,Tapentadol [INN],GTPL7477,H8A007M585,DTXSID30170003,TAPENTADOL [MART.],Q414463,175591-23-8,CG5503,D06007,BN 200,BCP9000118,Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-,BDBM50386381,3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol,UNII-H8A007M585,Tapentadol,Tapentadol (USAN/INN),(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol,CG 5503,3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol,CHEBI:135935,NSC 759619,TAPENTADOL [WHO-DD],AKOS015951190,NSC-759619,phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-,Nucynta ER,CHEMBL1201776,BN-200,3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol,(R,R)-Tapentadol,Nucynta,TAPENTADOL [USAN],ZINC20783,CG5503 IR,HSDB 8309,DEA No. 9780,CG5503 (BASE),BN 200 (BASE),Tapentadol [USAN:INN],FT-0699883

Estimated data

Solubilidad: -2.187 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 74.1% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.